| 2026-09-02 | 8-K | Form 8-K, Item 5.02 |
| 2026-08-25 | Press release | Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors |
| 2026-08-25 | Press release | Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors |
| 2026-08-25 | 8-K | Form 8-K, Item 5.02 |
| 2026-08-13 | Press release | Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates |
| 2026-08-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-13 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-12 | Deck | Parabilis Corporate Presentation |
| 2026-06-11 | Press release | Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Optio |
| 2026-06-11 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-10 | Press release | PDF Version |
| 2026-06-09 | Press release | Parabilis Medicines Announces Pricing of Upsized Initial Public Offering |
| 2026-06-09 | SEC filing | Form S-1/A |
| 2026-06-04 | SEC filing | Form S-1/A |
| 2026-05-18 | Press release | Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ |
| 2026-05-07 | Press release | Parabilis Medicines Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors |
| 2026-04-14 | Press release | Parabilis Medicines Expands Executive Leadership Team |
| 2026-03-11 | Press release | Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receive |
| 2026-03-05 | Press release | Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Ad |
| 2026-01-08 | Press release | Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical D |
| 2025-11-12 | Press release | PDF Version |
| 2024-01-04 | Press release | PDF Version |
| Press release | Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platf |
| Press release | Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program |
| Press release | Parabilis Medicines Presents Clinical Data Demonstrating First-Ever Drugging of Key Cancer Driver with FOG-001 |
| Press release | Parabilis Medicines Presents Clinical and Preclinical Data Demonstrating Broad Potential of Helicon™ Peptides at AACR-NC |
| Press release | Parabilis Medicines to Present Overview of Ongoing Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at Upcoming Me |
| Press release | Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer |
| Press release | FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies |